Ypsomed has patented a system for controlling glucose levels in patients. The system includes a medication delivery device and a controller that determines insulin doses based on pharmacokinetic profiles. It can switch between different types of insulin based on glycemic patterns or user input. GlobalData’s report on Ypsomed gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Premium Insights Ypsomed Holding AG - Company Profile

Buy the Report

Premium Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Ypsomed, was a key innovation area identified from patents. Ypsomed's grant share as of February 2024 was 46%. Grant share is based on the ratio of number of grants to total number of patents.

System for controlling glucose with insulin delivery device

Source: United States Patent and Trademark Office (USPTO). Credit: Ypsomed Holding AG

A recently granted patent (Publication Number: US11901060B2) discloses a system designed to control glucose levels in patients by delivering insulin through a medication delivery device. The system includes a controller with control logic that utilizes a model predictive controller algorithm to determine the appropriate medication dose based on the pharmacokinetic profile of the insulin being administered. The system can automatically switch from a first type of insulin to a second type with a different pharmacokinetic profile in response to changes in the patient's glycemic pattern or user notifications. This transition allows for more precise dosing tailored to the patient's needs.

Furthermore, the system's control logic can adjust various model parameters, such as insulin sensitivity and basal rate, to optimize glucose control based on factors like meal bolus dosing aggressiveness and physiological glucose targets. The system also incorporates features like detecting the onset of the dawn phenomenon and initiating alarms before algorithm execution. Additionally, the system can determine the type of insulin required by comparing the patient's current glucose curve with a known curve, ensuring accurate dosing. Overall, this patented system offers a sophisticated and adaptive approach to insulin delivery, enhancing the management of glucose levels in patients with precision and efficiency.

To know more about GlobalData’s detailed insights on Ypsomed, buy the report here.

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.